Congress mandates pandemic testing blueprint—with private industry at the table

What it does

This bill requires the Secretary of Health and Human Services to develop and publicly release a plan for rapidly developing, validating, manufacturing, and distributing diagnostic tests during public health emergencies (such as pandemics or bioterrorism threats). The plan must describe processes for scaling testing capacity, identify domestic manufacturing capabilities, evaluate new testing technologies, and coordinate between government agencies, private manufacturers, laboratories, and states. The Secretary must release the plan within one year and update it every three years.

Why we flagged it

The bill's core function is to mandate development of a diagnostic testing preparedness plan for public health emergencies. It is a planning and coordination requirement, not a funding mechanism or regulatory change, and serves broad public health readiness.

What the text implies

• The bill authorizes the Secretary to contract with private entities to build domestic testing capacity, which may create long-term procurement relationships and subsidize private diagnostic manufacturers through government contracts without explicit appropriations limits.
• The plan's requirement to assess 'novel technologies and platforms' may accelerate adoption of unproven or proprietary diagnostic methods if they are included in the preparedness framework, potentially locking in vendor dependencies.
• The coordination mandate with 'device manufacturers, clinical and reference laboratories, and medical product distributors' gives private industry a formal seat at the planning table, potentially influencing which technologies are prioritized in the public plan.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a binding planning requirement that improves public health preparedness and transparency by mandating a publicly available roadmap for diagnostic testing during emergencies. Citizens benefit from faster, more coordinated testing responses during future health crises, and the public disclosure requirement ensures accountability and prevents ad-hoc decision-making.

Who stands to gain

• diagnostic test manufacturers
• clinical and reference laboratories
• medical device companies
• medical product distributors

Named in the bill

Secretary of Health and Human Services, Public Health Service Act, Section 319B, States, Indian Tribes and Tribal organizations, device manufacturers, clinical laboratories, reference laboratories, medical product distributors

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Feb 7, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 7, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $180,000 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Mariannette Miller-Meeks, the sponsor, reported $2,407,952 in PAC receipts in the 2026 cycle.

• F Hoffmann-la Roche Ltd and Its Affiliates — $180,000 on 2 filings

Lobbying Disclosure Act filings through Jul 15, 2026. A filing shows who paid to lobby on a bill it names, not what changed.